Back

FLIP(L) determines p53 induced life or death

Lees, A.; McIntyre, A. J.; Falcone, F.; Crawford, N. T.; McCann, C.; Quinn, G. P.; Roberts, J. Z.; Sessler, T.; Gallagher, P. F.; McAllister, K.; McLaughlin, K.; Allen, W. L.; Holohan, C.; Egan, L. J.; Ryan, A. E.; Labonte-Wilson, M.; Dunne, P. D.; Wappett, M.; Coyle, V. M.; Johnston, P.; Kerr, E. M.; Longley, D. B.; McDade, S. S.

2019-11-28 cancer biology
10.1101/858688 bioRxiv
Show abstract

How p53 differentially activates cell cycle arrest versus cell death remains poorly understood. Here, we demonstrate that upregulation of canonical pro-apoptotic p53 target genes in colon cancer cells imposes a critical dependence on the long splice form of the caspase-8 regulator FLIP (FLIP(L)), which we identify as a direct p53 transcriptional target. Inhibiting FLIP(L) expression with siRNA or Class-I HDAC inhibitors promotes apoptosis in response to p53 activation by the MDM2 inhibitor Nutlin-3A, which otherwise predominantly induces cell-cycle arrest. When FLIP(L) upregulation is inhibited, apoptosis is induced in response to p53 activation via a novel ligand-independent TRAIL-R2/caspase-8 complex, which, by activating BID, induces mitochondrial-mediated apoptosis. Notably, FLIP(L) depletion inhibits p53-induced expression of the cell cycle regulator p21 and enhances p53-mediated upregulation of PUMA, with the latter activating mitochondrial-mediated apoptosis in FLIP(L)-depleted, Nutlin-3A-treated cells lacking TRAIL-R2/caspase-8. Thus, we report two previously undescribed, novel FLIP(L)-dependent mechanisms that determine cell fate following p53 activation.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.